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Open access under CCAutoimmune and cholestatic liver disease account for a signiﬁcant
part of end-stage liver disease and are leading indications for liver
transplantation. Especially cholestatic liver diseases (primary
biliary cirrhosis and primary sclerosing cholangitis) appear to be
different from other chronic liver diseases with regards to patho-
genesis. Portal ﬁbroblasts located in the connective tissue
surrounding bile ducts appear to be different from hepatic stellate
cells with regards to expression of marker proteins and response
the proﬁbrogenic and mitogenic stimuli. In addition there is
increasing evidence for a cross talk between activated chol-
angiocytes and portal myoﬁbroblasts. Several animal models have
improved our understanding of the mechanisms underlying these
chronic liver diseases. In the present review, we discuss the
current concepts and ideas with regards to myoﬁbroblastic cell
populations, mechanisms of ﬁbrosis, summarize characteristic
histological ﬁndings and currently employed animal models of
autoimmune and cholestatic liver disease.
 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Chronic liver disease is characterized by continuous liver cell injury followed by compensatory
proliferation, inﬂammatory cell inﬁltration and deposition of extracellular matrix (ECM) proteins by
myoﬁbroblasts. Cirrhosis is the end result of this wound healing response and is characterized by theerology and Hepatology, Department of Internal Medicine III, Medical
, A-1090 Vienna, Austria. Tel.: þ43 140 400 4741; fax: þ43 140 400 4735.
ac.at (M. Trauner).
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Abbreviations
ECM Extracellular matrix
PBC primary biliary cirrhosis
PSC primary sclerosing cholangitis
HSC hepatic stellate cells
STAP stellate cell activation-associated protein
CRBP cellular retinol-binding proteins
LRAT lecithin-retinol acyltransferase
GFAP glial ﬁbrillary acidic protein
PDGF platelet-derived growth factor
FGF-2 ﬁbroblast growth factor-2
TGFb transforming growth factor b
HGF hepatocyte growth factor
VEGF vascular endothelial growth factor
CTGF connective tissue growth factor
IGF1 insulin-like growth factor 1
NGF nerve growth factor
MCP-1 monocyte chemoattractant protein-1
EMT epithelial to mesenchymal transition
VDR farnesoid X receptor (FXR), vitamin D receptor
LXR liver X receptor
AMAs antimitochondrial antibodies
PDC-E2 E2 subunit of pyruvate dehydrogenase complex
UDCA ursodeoxycholic acid
AE2 anion exchanger 2
KO knockout
pANCA perinuclear antineutrophil cytoplasmatic antibody
ERCP endoscopic retrograde cholangio-pancreaticography
MRCP magnetic resonance cholangio-pancreaticography
CFTR cystic ﬁbrosis transmembrane conductance regulator
DCC 3,5-diethoxycarbonyl-1,4-dihydrocollidine
ANIT alpha-naphthylisothiocyanate
AIP autoimmune pancreatitis
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ment of liver tissue by connective scar tissue is associated with loss of normal liver function. Immune
mediated and cholestatic liver disease progress to liver cirrhosis and end-stage liver disease if not
treated. Indeed, cholestatic liver diseases are a frequent cause for liver transplantation (w15%) [1].
In this article we will discuss the cellular sources and mediators of ﬁbrosis in cholestatic and
autoimmune liver disease and highlight primary biliary cirrhosis (PBC) and primary sclerosing chol-
angitis (PSC) and their animal models as paradigms of cholestatic disorders, which can serve as model
diseases for understanding the mechanisms of biliary ﬁbrosis.
Cellular sources and mediators of ﬁbrosis in cholestatic and autoimmune liver disease
Myoﬁbroblastic cell populations in liver ﬁbrosis with special emphasis of cholestasis
Hepatic myoﬁbroblasts are a heterogeneous population of cells characterized by expression on
a-smooth muscle actin and might be discriminated by tissue localization, expression of different
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main source of collagen in most ﬁbrotic liver diseases. In the normal liver, HSC reside in a quiescent
state in the space of Dissé and are the major storage site of vitamin A in the human body. Following
liver injury HSC undergo a phenotypic transformation and switch to a proliferative, contractile,
migratory, inﬂammatory and most importantly ﬁbrogenic phenotype [2]. However, the simple para-
digm that all collagen found in cirrhotic liver is produced by activated HSC has grown far more
multifaceted. It has become increasingly clear that myoﬁbroblasts are a heterogeneous population of
cells and do not derive entirely from quiescent HSC [3]. Portal ﬁbroblasts located in the connective
tissue around portal tracts appear to be of particular importance in ischemic and cholestatic liver
disease and are different from HSC with regards to expression of marker proteins and response the
proﬁbrogenic and mitogenic stimuli (Fig. 2) [4]. In this is respect it was shown that isolated portal
ﬁbroblasts express elastin but not desmin, whereas HSC consistently express desmin but never elastin
[5]. In a comparative proteomic study several proteins were identiﬁed that discriminate between HSC
and myoﬁbroblasts. Cytoglobin (also known as stellate cell activation-associated protein – STAP)
appears to be the best marker for distinguishing HSC from portal myoﬁbroblasts [6]. HSC were ﬁrst
successfully isolated based on their characteristic low density due to cytoplasmic lipid droplets using
a discontinuous gradient of arabinogalactan [7]. These lipid droplets are the major site for storage of
vitamin A and its metabolites in the body of vertebrates and cause characteristic autoﬂuorescence of
retinoids observed in HSC cultures and in unstained frozen sections. Proteins involved in vitamin A
metabolism, including cellular retinol-binding proteins (CRBP) or lecithin-retinol acyltransferase
(LRAT) are therefore potential markers for speciﬁc identiﬁcation of HSC [5,8,9]. Accordingly, portal
myoﬁbroblasts do also not form lipid droplets when retinol is added to the culture media [5]. Other
markers with variable expression in portal myoﬁbroblasts are neurotrophin NT-3 and ﬁbroblast marker
TE-7 [4,10]. Vimentin, vinculin, synemin, glial ﬁbrillary acidic protein (GFAP), neurotrophin receptor
p75 appear to be a marker expressed by both cell types [10,11]. However, only a minority of these
markers was studied thoroughly both in vitro and in vivo. In addition there are reports indicating that
other cells also express some of these markers, e.g. cellular retinol binding proteins, cytoglobin, p75.Fig. 1. Myoﬁbroblastic cell populations in the liver. Myoﬁbroblasts in the liver differ with regards to their localization within a liver
lobule (A). HSC are located in the space of Dissé (B). Portal ﬁbroblasts surround cholangiocytes in the portal tracts (C). Smooth muscle
cells in vessel walls and surrounding centrolobular veins might also contribute to ECM deposition (D). In ﬁbrotic liver, interface
myoﬁbroblasts are located at the border between ﬁbrotic septa and neighboring parenchyma called have been identiﬁed (E).
Fig. 2. Differential expression of marker proteins by portal myoﬁbroblasts and HSC. Whereas portal myoﬁbroblasts and hepatic
stellate cells share expression of some marker proteins, some proteins appear to be speciﬁc for each particular cell type.
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betweenportalmyoﬁbroblasts andHSC.Whereas,platelet-derivedgrowth factor (PDGF) is themostpotent
mitogenic stimuli for HSC it inhibits portal ﬁbroblasts proliferation and myoﬁbroblastic differentiation
[5,12]. In contrast, ﬁbroblast growth factor-2 (FGF-2) causes portal ﬁbroblast proliferation. Portal myoﬁ-
broblasts produce signiﬁcant amounts of transforming growth factor b2 (TGFb2) and, unlike activatedHSC
express all three TGFb receptors and their proliferation is inhibited by TGFb1 and TGFb2 [12]. Myoﬁbro-
blastic differentiation of portal ﬁbroblasts was shown to depend on both TGFb and matrix stiffness [5].
Interestingly, increasing the stiffness of the culture matrix is associated with increased myoﬁbroblastic
phenotype suggesting that portal myoﬁbroblasts differentiate as a function of mechanical tension [5].
The term interface myoﬁbroblasts is used by some authors to speciﬁcally refer to myoﬁbroblasts at
the edge of between ﬁbrotic septa and neighboring parenchymal cells [13]. In addition, smooth muscle
cells in vessel walls (pericytes) and myoﬁbroblasts surrounding centrolobular veins might contribute
to ECM deposition in chronic liver disease [14]. At present there are no protocols established for
selective isolation of these cells. However, both cell types were reported to express vinculin, p75,
synemin and vimentin [10].
Cholangiocytes – victims and culprits in cholestatic liver disease
There also appears to be extensive paracrine cross-talk between cholangiocytes (bile duct epithelial
cells) and portal ﬁbroblasts in cholestatic liver disease (Fig. 3). In many forms of liver injury especially
in cholangiopathies an increased number of proliferating small bile ducts can be observed which is
referred to as ‘ductular reaction’. These newly formed, ‘reactive’ cholangiocytes are characterized by
increased expression of anti-apoptotic genes (Bcl-2), neuroendocrine molecules (chromogranin A,
NGF), adhesion molecules (NCAM, ICAM), co-stimulatory molecules (MHC II, CD40), cytokines (TNFa,
IL-1, IL-6, IL-8, IFNg), chemokines (MCP-1), growth factors (HGF, VEGF, CTGF, IGF1, NGF) and proﬁ-
brogenic stimuli (PDGF, TGFb2, endothelin-1) which have autocrine and paracrine effects on
Fig. 3. Cross-talk between cholangiocytes and myoﬁbroblasts. Following cholestatic liver injury an increased number of bile ducts
can be observed. These cholangiocytes are characterized by increased expression of neuroendocrine molecules, adhesion molecules,
co-stimulatory molecules, cytokines, chemokines, growth factors and proﬁbrogenic stimuli which have autocrine and paracrine
effects on myoﬁbroblasts activation, migration and proliferation.
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also affect Kupffer cells, hepatocytes or endothelial cells functions. Furthermore, in normal healthy
liver, portal ﬁbroblasts express ecto-nucleotidase NTPDase2, which converts ATP to AMP. Following
cholestatic liver injury portal myoﬁbroblasts loose expression of NTPDase2 allowing activation of
basolateral P2Y receptors expressed by bile duct epithelia cells resulting in MAPK mediated prolifer-
ation of cholangiocytes [27]. Bile duct epithelial cells are also as source of chemokines. In this respect it
was shown that the monocyte chemoattractant protein-1 (MCP-1)/CCL2 is upregulated in biliary
ﬁbrosis by cholangiocytes and MCP-1 increases aSMA and a(1)-procollagen production in portal
myoﬁbroblasts [28]. The tight relationship between cholangiocyte proliferation and ﬁbrogenesis has
lead to the suggestion that the ductular reaction is the ‘pacemaker of portal ﬁbrosis’. Importantly,
‘quiescent’ cholangiocytes do not produce these peptides.
Epithelial to mesenchymal transition as a potential source of myoﬁbroblasts
It was suggested that myoﬁbroblasts might also originate from epithelial cells via epithelial to
mesenchymal transition (EMT) in liver ﬁbrosis. According to this concept cholangiocytesmight serve as
another source of myoﬁbroblasts via EMT to contribute to portal tract ﬁbrosis in cholestatic liver injury
[29–32]. However, recent evidence suggests that EMT is a cell culture phenomenon, which does not
occur in vivo and that initial studies relied on inappropriate methodology leading to interpretational
pitfalls [33–35].
Role of bile acids and activated nuclear receptors driving ﬁbrosis in cholestatic liver disease
Several key transcriptional regulators including ligand-activated nuclear receptors orchestrate the
transdifferentiation of HSC from a quiescent to an activated myoﬁbroblastic-like phenotype producing
ECM in the ﬁbrotic liver. Factors increasing as a results cholestasis might also be pro-ﬁbrogenic
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HSC activating the protein kinase C/extracellular signal-regulated kinase/p70S6K-dependent pathway
causing cell proliferation [36]. Stimulation of the nuclear bile acid/farnesoid X receptor (FXR) has been
suggested to play a key role since a series of studies suggested that FXR can modulate HSC activity by
restoring peroxisome proliferator-activated receptor g (PPARg) signalling and by FXR-SHP-dependent
inhibition of AP-1 signalling on downstream proﬁbrogenic targets [37]. In contrast to these ﬁndings,
a recent study in different mouse models of biliary type and non-biliary type of ﬁbrosis revealed that
lack of FXR signiﬁcantly reduces ﬁbrosis of the biliary type, while having no impact on non-cholestatic
liver ﬁbrosis [38]. Notably, FXR expressionwas virtually undetectable inmouse HSC andmyoﬁbroblasts
and only minimal in human HSC [38]. Except vitamin D receptor (VDR), which can also be activated by
hydrophobic bile acids, and liver X receptor (LXR), expression of other nuclear receptors is rather low in
activated mouse and human HSC [38]. Despite these recent molecular insights into bile acid signalling,
the direct role of bile acids in driving liver ﬁbrosis still remains to be deﬁned. Rather, bile acids appear
to promote ﬁbrosis indirectly through hepatocyte injury [39].
Primary Biliary Cirrhosis
Primary biliary cirrhosis is a slowly progressive cholestatic autoimmune liver disease of unknown
etiology [40]. It affects individuals of all ethnicities and accounts for w1% of deaths from cirrhosis
worldwide [41]. Despite being a rather rare cause of cirrhosis, PBC represent a leading indication for
liver transplantation [42]. Interestingly, the incidence of PBC is increasing worldwide and PBC is
typically diagnosed inwomen in their 5th-7th decade. Antimitochondrial antibodies (AMAs) against the
inner lipoyl domain of the E2 subunit of pyruvate dehydrogenase complex (PDC-E2) are the diagnostic
hallmark [43]. Histologically, PBC is characterized by chronic, nonsuppurative cholangitis and can be
divided into four distinct stages: Stage I is characterized by inﬂammatory cell inﬁltrate consisting of
lymphocytes, plasma cells and eosinophil granulocytes restricted to the portal triad. Eventually
inﬂammation extends into hepatic parenchyma referred to as interface hepatitis (stage II). Lympho-
cytes also form bridge-like extensions into the lobes and may be the forerunners of ﬁbrous septa.
Fibrotic septa extend from the portal tracts and eventually link portal tracts to each other forming the
so-called ‘bridging ﬁbrosis’ (stage III). Complete distortion of the liver architecture by numerous
ﬁbrotic septa then leads to cirrhosis with the existence of regenerative nodules (stage IV) [44,45.] Three
independent studies have shown that patients with PBC histologically progress by one stage every 1.5
years [44,46,47]. These stages are not always easy to discriminate in biopsy specimen, because lesions
are not evenly distributed throughout the liver and partly because the stages may overlap. PBC- typical
granulomas are present in w15% of patients but are frequently missed in small percutaneous biopsy
specimens. Sites of bile duct destruction are marked by aggregates of lymphoid cells and bile duct
proliferation might also be observed at histological examination. The median survival for symptomatic
patients with PBC ranges from 5 to 8 years from the onset of symptoms [48]. Secondary biliary cirrhosis
is most often caused by a previous surgical procedure resulting in bile duct injury. However, other
causes of bile duct obstruction such as stones, malignancies, cysts, or parasites must also be considered.
Mouse Models of PBC
NOD.c3c4 mice
The NOD.c3c4 mouse was the ﬁrst spontaneous mouse model of PBC. It is characterized by
destructive cholangitis, granuloma formation and eosinophilic inﬁltration. In contrast to human PBC
the extrahepatic biliary ducts are also affected. Livers are characterized by biliary cyst formation and
adjacent lymphocytic inﬁltrates. These mice also develop PDC-E2 antibodies, which precedes the
development of liver abnormalities and ANA [49]. These ﬁndings are equivalent to the occurrence if
anti-PDC-E2 in humans several years before the overt onset of PBC. Importantly, depletion of T-cells
protects from biliary disease indicating that CD4þ and CD8þ T-cells inﬁltrating the biliary epithelium
play a crucial role in the pathogenesis of this disease. Accordingly, adoptive transfer of splenocytes or
CD4þ T-cells into NOD.c3c4-scid mice causes autoimmune biliary disease, indicating that T-cells play
a crucial role in this animal model of PBC [50].
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Studies in TGFb1 knockout (KO) mice indicated that TGFb1 is one of the key negative regulators of
immune homeostasis and its absence causes autoimmune disease in several organs. To delineate the
role of TGFb1 in T cell homeostasis, mice expressing a dominant-negative (dn) TGFb1 receptor type II
under the control of the CD4 promoter were generated resulting in speciﬁc abrogation of TGFb1
signaling in CD4 positive T cells. These mice also develop autoimmune inﬂammatory disease in
multiple other organs including the lungs and intestine [51]. Remarkably, dnTGFbRII mice mimic
several characteristic features of human PBC, including lymphocytic cell inﬁltration with periportal
inﬂammation analogous to histological ﬁndings in patients, a serum cytokine proﬁle typical for PBC
characterized by increased levels of IFNg, TNFa, IL-6 and IL-12p40, and most importantly spontaneous
production of AMAs directed to the same mitochondrial autoantigens [52].
IL2R-a KO mice
The IL-2R consists of three subunits: a (CD25), b (CD122), and g (CD132). IL-2Ra transduces a crucial
signal for T cell proliferation and is responsible for the development, activity and expansion of the
CD4þCD25þ regulatory subset of T cells (Tregs), which reduces proliferation, and activation of effector
T cells [53–55]. Tregs play a pivotal role in the adaptive immune system and limit autoreactive T cell
responses in many different models of autoimmunity. IL2Ra KO mice show many characteristic
features like those in human PBC: IL- increased serum levels of IgG and IgA, mild interface hepatitis and
bile duct injury [56]. However, these mice also develop an ulcerative colitis-like disease, usually
associated with PSC but not PBC in humans.
Ae2a,b KO mice
The Cl-/HCO3- anion exchanger 2 (AE2) mediates Cl/HCO3 exchange across the plasma
membrane and plays a critical role in the regulation of in intracellular pH levels and transepithelial
acid-base transport, including biliary bicarbonate excretion stimulated by secretin. Notably, AE2
expression and activity is reduced in liver and mononuclear cells of patients with PBC [57–59]. It was
therefore proposed that reduced expression of AE2 and resulting changes in bile composition promote
bile duct injury [57–59]. Interestingly, AE2 deﬁciency inmice alters pH homeostasis in several cells and
results in increased perinatal mortality, azoospermia, decreased gastric acid secretion, bone abnor-
malities, growth retardation and deafness [60,61]. AE2 KO mice display splenomegaly, elevated pH in
splenocytes, increased expression of IFNg and IL12 as wells as increased number of CD8(þ) T cells but
reduced numbers of CD4/FoxP3(þ)T cells. Most AE2 deﬁcient mice also show increased serum levels of
IgM, IgG and alkaline phosphatase and develop AMA. However, only one third of mice display extensive
portal inﬂammation and ﬁbrosis of the portal tracts [62].
Chemical xenobiotics as initiators of autoimmune liver disease
Accumulating evidence suggests that environmental factors play a key role in the pathogenesis of
PBC. It was suggested that replacement of the lipoyl domain of PDC-E2 by a chemical xenobiotic mimic
would be sufﬁcient to break self-tolerance. In a screenmore than100potential xenobioticswere coupled
to PDC-E2, spotted onmicroarray slides andwere assayed for Ig reactivity using sera from patients with
PBC. This led to the identiﬁaction of 2-octynoic acid which commonly occurs in perfumes, soaps,
detergents, lipsticks, toilet waters, facial creams, and many common food ﬂavorings as a potential
xenobiotic [63]. Remarkably, C57BL/6 mice immunized with 2-octynoic acid coupled to bovine serum
albumin develop antibodies to PDC-E2 and increase serum levels of TNFa and IFNg. Histologically these
mice are characerized by inﬂammatory cell inﬁltration and the development of biliary disease [64].
Autoimmune Hepatitis
Autoimmune hepatitis (AIH) is characterized by elevated serum transaminase levels, hyper-
gammaglobulinemia, presence of autoantibodies, and chronic hepatitis [65]. Similar to PBC it mostly
affects women (w75%). The histological hallmark of AIH is interface hepatitis, which however is not
diagnostic for AIH as it can also be found in other chronic liver diseases (e.g. viral hepatitis). Hepato-
cellular damage and a mixed inﬂammatory cell inﬁltrate consisting of lymphocytes, plasma cells and
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Bridging necrosis is common and surviving hepatocytes often form gland-like structures called ‘hep-
atitic rosettes’. The degree of inﬂammation may vary and cholestasis, bile duct damage or even ducto-
penia might be present in some patients. Furthermore, in rare instances the principal features at initial
presentation are centrilubular necrosis or inﬂammation in perivenular areas, typically seen in acute
hepatitis [66]. Cirrhosis is observed in one third of patients at initial diagnosis but is reversible following
immunosuppressive treatment. Patients with AIH usually respond rapidly to corticosteroid treatment
and follow-up biopsies show varying degrees of resolution of the necro-inﬂammatory process. Fibrosis
andother structural changesmayalso improve. Importantly, histological features canoverlapwith those
of PSC or PBC and a careful histological examination is therefore mandatory [67,68].
Mouse Model of AIH
TGFb1 KO mice
TGFb1 plays a key role in many cellular functions, including the control of cell growth, proliferation,
differentiation and apoptosis and therefore affects biological processes such as tissue remodeling and
wound healing, carcinogenesis, and immune responses. Most importantly, TGFb1 is a negative regu-
lator of survival, activation, proliferation and effector functions of several cells of the immune system.
Accordingly, mice lacking TGFb1 display excessive inﬂammation characterized by inﬂammatory lesions
primarily in the heart and lungs resembling autoimmune disorders [69].
Breeding TGFb1 KOmice into the BALB/c background dramatically modiﬁed the phenotype of TGFb1
KOmice and resulted in the development of spontaneous hepatitis resembling human AIH. Accordingly,
BALB/c-TGFb1 KO mice develop lethal inﬂammatory hepatitis that was not observed in other genetic
backgrounds. Livers of BALB/c-TGFb1 KO mice show accumulation of activated CD4(þ) T cells charac-
terized by high expression of IFNg. TGF-b1/IFN-g double KO mice do not develop necroinﬂammatory
hepatitis suggesting that IFNg plays a critical role in this mouse model [70]. These ﬁndings suggest that
TGFb1 is a critical immunosuppressive cytokine that prevents development of autoimmune liver disease.
Primary Sclerosing Cholangitis
Primary sclerosing cholangitis is characterized by chronic inﬂammation and obliterative ﬁbrosis of
the intra- and/or extra-hepatic biliary tree. PSC typically presents during the 3rd-4th decade [71], and
the most recent epidemiological study indicates that PSC is as common as PBC and AIH [72]. Auto-
immune features are common in PSC, antinuclear antibodies are present in up to 50% and perinuclear
antineutrophil cytoplasmatic antibody (pANCA) in 80% of cases [73]. Seventy to 80% of patients with
PSC have or will develop IBD, mainly ulcerative colitis, and w15% of patients develop chol-
angiocarcinoma [74–76]. PSC mostly affects medium- and large- sized bile ducts, which are typically
not seen in percutaneous liver biopsy specimen. Accordingly, endoscopic retrograde cholangio-pan-
creaticography (ERCP) and more recently magnetic resonance cholangio-pancreaticography (MRCP)
are considered the gold standard for the diagnosis of PSC.
Small duct PSC refers to a variant of PSC that is characterized by cholestasis and histological features
typical for PSC but mostly normal bile ducts on cholangiography [77]. In contrast to PSC, small duct PSC
can only be diagnosed by percutaneous liver biopsy, as small ducts are typically present in biopsy
specimen. Small duct PSC has been reported to be less rapidly progressive than large duct PSC with
a lower incidence of cholangiocarcinoma. Notably 20% of patients develop regular, large duct PSC [78].
The characteristic histological feature of PSC is concentric periductal ﬁbrosis (‘onion-skinning’) that
gradually progresses and eventually leads to obliteration and loss of interlobular bile ducts. Portal
inﬂammation and periductal edema are other characteristic histological features. The duct epithelium
may show various degrees of atrophy and might even disappear, leaving a characteristic ﬁbro-oblit-
erative scar. Major bile ducts are often inﬂamed, ulcerated or dilated. Ludwig proposed a histological
staging system based on characteristic features as well as extent of inﬂammation and ﬁbrosis. The
stages are similar to those of PBC: Stage I is marked by bile duct injury and portal inﬂammation with
minimal ﬁbrosis; Stage II by expansion of portal tracts, periportal ﬁbrosis and further inﬂammation;
Stage III by ﬁbrous septa, bridging ﬁbrosis, and progressive ductopenia; Stage IV by cirrhosis.
M. Penz-Österreicher et al. / Best Practice & Research Clinical Gastroenterology 25 (2011) 245–258 253Animal models of PSC
Rat model of small bowel overgrowth
Bacterial cell wall components have been suggested to play a key role in the pathogenesis of PSC by
triggering the innate immune system. Surgical creation of blind loops of the jejunum in rats promotes
bacterial overgrowth associated with bacterial translocation and exposure of Kupffer cells to bacterial
cell wall components, especially peptidoglycan-polysaccharides [79]. Histologically this animal model
is characterized by portal inﬂammation, bile duct proliferation, interlobular bile duct destruction and
biliary ﬁbrosis. Cholangiography shows strictures of bile ducts with intervening areas that are
irregulary tortuous and dilated [80]. This appears to be TLR4 independent, since treatment with
gentamicin or polymyxin B, targeting lipopolysaccharide does not affect development of liver disease.
In contrast, metronidazole or tetracycline treatment prevents hepatic [81].
Mdr2 KO mouse
The multidrug resistance gene (mdr2) encodes a P-type glycoprotein critical for the transport of
phosphatidylcholine into the outer leaﬂet of the canalilcular cell membrane, facilitating the subsequent
extraction of bile acids and excretion into the bile. Accordingly, mdr2 KOmice lack phosphatidylcholine
excretion into bile, which renders bile toxic because of an increased concentration of free non-micellar
bile acids [82].Mdr2 KOmice display accumulation of toxic bile salts in the intrahepatic biliary system,
which eventually disrupts tight junctions and basement membranes of bile ducts. This causes regur-
gitation of bile acids into portal tracts leading to non-suppurative inﬂammatory cholangitis, onion-skin
type periductal ﬁbrosis and ductular proliferation. Moreover, this results in activation of periductal
myoﬁbroblasts, periductal ﬁbrosis causing obliterative cholangitis owing to atrophy and death of bile
duct epithelial cells at 2 months of age [83]. At the age of 4–6 months mdr2 KO mice start to develop
multiple foci in the liver parenchyma, culminating in macroscopically visible tumor nodules. Micro-
scopically, these lesions consist of sheets of atypical hepatocytes with loss of orderly structured
architecture and reticulin pattern [84]. The mdr2 KO mouse therefore represents a valuable model to
investigate the development of HCC in an inﬂammatory and ﬁbrotic setting [85].
CFTR
Asmentioned earlier, changes in bile composition as a consequence of altered pH for instancemight
affect progression of disease. In this respect, an increased prevalence of variations in the cystic ﬁbrosis
transmembrane conductance regulator (CFTR) gene was noted in a subset of patients with IBD and PSC
[86]. Interestingly, deletion of exon 10 of the CFTR gene in mice does not result in liver disease.
However, induction of colitis in these mice causes bile duct injury characterized by portal tract and bile
duct inﬁltration with mononuclear cells and bile duct proliferates [87].
Chemical xenobiotics as initiators of sclerosing cholangitis liver disease
Feeding of 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DCC) represents another valuable mouse
model to investigate the mechanisms of xenobiotic-induced cholangiopathies and subsequent biliary
ﬁbrosis. DCC feeding causes increased biliary secretion of porphyrin with subsequent inﬂammation
associated with expression of TNFa, VCAM and osteopontin by bile duct epithelial cells. This leads to
pericholangitis, ductular reaction and biliary ﬁbrosis caused by activation of periductal myoﬁbroblasts
[88]. Litocholic acid feeding in mice leads to segmental bile duct obstruction, destructive cholangitis
and periductal ﬁbrosis. At ultrastructural level small bile ducts are frequently obstructed by crystals,
suggesting that mechanical injury and subsequent obstruction is crucial for the development of bile
duct injury [89]. Alpha-naphthylisothiocyanate (ANIT) is another drug, which is toxic to bile ducts and
induces ductular proliferation. Oral administration of ANIT to rats causes inﬂammatory inﬁltrates in
portal tracts progressing to portal inﬂammation and extensive ﬁbrosis over the course of 2 weeks [90].
IgG4-related sclerosing cholangitis
Sclerosing cholangitis is sometimes also observed in patients with autoimmune pancreatitis (AIP)
and was initially referred to as atypical PSC. IgG4-antibody stained plasma cells can be found in various
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to distinguish AIP from other pancreatic diseases. Accordingly sclerosing cholangitis associated with
AIP is now referred to as IgG4-related sclerosing cholangitis and can be discriminated from PSC by
quantiﬁcation of serum IgG4 levels and IgG4 immunostaining of biopsy specimen. IgG4-related scle-
rosing cholangitis shows cholangiographic features similar to PSC but in contrast to PSC both AIP and
IgG4-related sclerosing cholangitis respond well to steroid therapy and biliary drainage[ [91–93].
Histological ﬁndings of IgG4-related sclerosing cholangitis include portal inﬂammation, large bile duct
damage, portal sclerosis, lobular hepatitis, and canalicular cholestasis [94].
Overlap syndromes
In the majority of cases the so-called ’overlapping-syndromes’ occur between AIH and PBC or AIH
and PSC. Depending upon diagnostic criteria and patient selection 2–19% of patients with PBC and
7–14% of patients with PSC have features that overlap with those of AIH. There are no standardized
criteria for deﬁnition of overlapping syndromes and overlapping features include symptoms,
biochemical tests, a variety of immunological ﬁndings as well as histology. Accordingly, patients with
overlap syndromes may present histological features of different immune-mediated liver diseases.
Outlook
There has been substantial increase in our understandingof themechanismsunderlying autoimmune
and cholestatic liver disease in the past years. However, only little is known about disease speciﬁc
mechanisms with regard to myoﬁbroblast activation and ECM deposition. For instance, the relative
contribution of HSC to cholestatic liver disease remains elusive. Whereas, most animal models of auto-
immune and cholestatic liver disease have provided signiﬁcant insights into the mechanisms leading to
autoimmunity and liver injury, only little is known about the pathways causingmyoﬁbroblast activation
and ECM deposition. The successful establishment of isolation protocols for different myoﬁbroblast cell
types and disease speciﬁc mouse models will help to address this and other questions in the future.Practice points
 Autoimmune and cholestatic liver disease are leading indications for liver transplantation
 PBC is typically diagnosed in women in their 5th-7th decade
 Antimitochondrial antibodies against the E2 subunit of pyruvate dehydrogenase complex are
the diagnostic hallmark of PBC
 Granulomas are present inw15% of patients with PBC
 AIH mostly affects women
 Interface hepatitis and hepatitic rosettes are typical histological features of AIH
 Cirrhosis is observed in one third of patients with AIH but is reversible following immuno-
suppressive treatment
 PSC typically presents during the 3rd-4th decade
 Other autoimmune diseases like inﬂammatory bowel disease are common in patients with PSC
 Antinuclear antibodies are present in w50% and perinuclear antineutrophil cytoplasmatic
antibody in w80% of patients with PSC
 Magnetic resonance cholangio-pancreaticography is the gold standard for the diagnosis of PSC
 IgG4-related sclerosing cholangitis can be observed in patients with autoimmune pancreatitis
 IgG4-related sclerosing cholangitis is characterized by increased IgG4 serum levels and
presence of IgG4-positive B-cells in biopsy specimen
 Overlapping-syndromes between AIH and PBC or AIH and PSC should be considered in the
differential diagnosis
 Overlapping features include symptoms, biochemical tests, immunological ﬁndings and histology
Research agenda
 Evaluation of the quantitative contribution of portal ﬁbroblasts and hepatic stellate cells to
ﬁbrosis in PBC and PSC
 Investigate long-term outcomes and evolution of ﬁbrosis in existing animal models of PBC,
PSC and AIH
 Establishment of new animal models of PBC and AIH that allow investigating myoﬁbroblast
activation and mechanisms of ﬁbrosis in these diseases
 Establishment of mouse models (GFP reporter mice, HSV-TK transgenic mice, Cre mice) that
allow to speciﬁcally follow, ablate and manipulate portal myoﬁbroblasts and hepatic stellate
cells in experimental liver ﬁbrosis
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